ABSTRACT
Background Data regarding critical care for patients with severe COVID-19 are limited. We aimed to describe and analyse the clinical course, multi-strategy management, and respiratory support usage for the severe COVID-19 at the provincial level.
Methods Using data from Sichuan Provincial Department of Health and the population-based multicentre cohort study, all microbiologically confirmed COVID-19 patients in Sichuan who met the national severe criteria were included from January 16 to March 15, 2020. All patients were followed-up from the day of inclusion, noted as Day one (D1), until discharge, death, or the end of the study.
Findings Out of 539 COVID-19 patients, 81 severe cases (15·0%) were identified. The median (IQR) age was 50 (39-65) years, 37% were female, and 53·1% had chronic comorbidities. All severe cases were identified before requiring mechanical ventilation. Among the five predefined criteria for severe illness, low PaO2:FiO2 ratio (<300 mmHg) was the most commonly reported, accounting for 87·7% of the severe diagnosed. By establishing provisional ICUs, all 81 patients were admitted to hospitals capable of providing critical care, among whom 51 (63·0%) were treated in provisional ICUs. On D1, 77 patients (95·1%) were admitted, 76 (93·8%) were administered by respiratory support, including 51 (67·9%) by conventional oxygen therapy (COT). By D28, 53 (65·4%) were discharged, three (3·7%) were deceased, and 25 (30·9%) were still hospitalized. COT, administered to 95·1% of the patients, was the most commonly used respiratory support and met 62·7% of the respiratory support needed, followed by high-flow nasal cannula (19·5%) and non-invasive mechanical ventilation (10%).
Interpretation The multi-strategy management for severe COVID-19 patients included early identification and timely critical care, including appropriate respiratory support in particular. Preparation of sufficient conventional oxygen equipment should be prioritized.
Funding This project was supported by Project of Novel Coronavirus Pneumonia in West China Hospital.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not a Clinical trials.
Funding Statement
The project was supported by Project of Novel Coronavirus Pneumonia in West China Hospital.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not Applicable.
